September 2013

Age-Related Macular Degeneration, Anti-VEGF Therapy, and Ophthalmic ImagingIs There a Best Practice?

Author Affiliations
  • 1Medical College of Wisconsin, Milwaukee

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2013;131(9):1124-1126. doi:10.1001/jamaophthalmol.2013.432

There is considerable debate on the management of neovascular age-related macular degeneration (AMD). Even brilliant minds cannot agree on which drug to use and how frequently to use it. Dosing regimens have been characterized in a number of ways (eg, continuous, discontinuous, pro re nata [PRN; “as needed”], treat and extend), each of which has its own variations among practitioners that can befuddle continuity of care. We are constantly trying to balance cost with benefit because the cost disparities between agency-approved and off-label uses are huge. Can we identify a guiding principle to help us? Is there a best practice?

First Page Preview View Large
First page PDF preview
First page PDF preview